Randomized Trialhigh evidence
Trientine for hypertrophic cardiomyopathy: a phase 2 trial.
European heart journal·July 15, 2026·PMID 42455121
Why it mattersHypertrophic cardiomyopathy lacks therapies directly targeting underlying myocardial hypertrophy and fibrosis. Trientine, a copper chelator, addresses proposed disease mechanisms by improving intracellular copper trafficking and reducing profibrotic signaling, offering a potential disease-modifying approach beyond symptom management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled